Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides

J Allergy Clin Immunol. 2014 Jul;134(1):239-240.e13. doi: 10.1016/j.jaci.2014.04.001. Epub 2014 May 3.

Authors

François Spertini¹, Yannick Perrin², Régine Audran², Céline Pellaton², Caroline Boudousquié², Nathalie Barbier², Anne-Christine Thierry², Vincent Charlon³, Christophe Reymond⁴

Affiliations

¹ Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address: [email protected].
² Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
³ Anergis SA, Epalinges, Switzerland.
⁴ Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Anergis SA, Epalinges, Switzerland.

PMID: 24797422
DOI: 10.1016/j.jaci.2014.04.001

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antigens, Plant / chemistry*
Antigens, Plant / immunology
Asthma / immunology
Asthma / therapy*
Conjunctivitis, Allergic / immunology
Conjunctivitis, Allergic / therapy*
Desensitization, Immunologic / methods*
Female
Humans
Immunization Schedule
Immunoglobulin E / blood
Immunoglobulin G / blood
Immunologic Memory
Injections, Subcutaneous
Middle Aged
Peptides / administration & dosage*
Peptides / adverse effects
Peptides / immunology
Rhinitis, Allergic / immunology
Rhinitis, Allergic / therapy*

Substances

Antigens, Plant
Immunoglobulin G
Peptides
Bet v 1 allergen, Betula
Immunoglobulin E